Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans.
Diabetes. 2008 May; 57(5):1246-53
Michael Müller
08 May 2008
|
Technical Advance
This is the first study to show the potential clinical relevance of FGF21 as a biomarker for metabolic syndrome, an interesting finding but that will have to be validated with many more patients.
FGF21 is an endocrine factor (not a specific adipokine) that has been mainly studied in mice or human cell lines and is induced during...
INDIVIDUAL SUBSCRIPTIONS
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.
Subscribe for $9.95/monthINSTITUTIONAL SUBSCRIPTIONS
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
Recommend to your LibrarianIf you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.
Request an Institutional Trialyour institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.